NovoCure Ltd - 8-K Filing
NovoCure reports Q3 2026 net revenues of $193.4 million and raises full-year 2026 revenue and Adjusted EBITDA guidance. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $NVCR
Read the full article at SEC EDGAR
Part of the story PG&E Corp - 8-K Filing (47 articles)